These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1009 related articles for article (PubMed ID: 15189267)
1. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267 [TBL] [Abstract][Full Text] [Related]
2. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236 [TBL] [Abstract][Full Text] [Related]
3. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR; Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346 [TBL] [Abstract][Full Text] [Related]
4. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324 [TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847 [TBL] [Abstract][Full Text] [Related]
6. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990 [TBL] [Abstract][Full Text] [Related]
7. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Degott C; Zafrani ES; Callard P; Balkau B; Poupon RE; Poupon R Hepatology; 1999 Apr; 29(4):1007-12. PubMed ID: 10094939 [TBL] [Abstract][Full Text] [Related]
8. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Batts KP; Jorgensen RA; Dickson ER; Lindor KD Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409 [TBL] [Abstract][Full Text] [Related]
10. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382 [TBL] [Abstract][Full Text] [Related]
11. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416 [TBL] [Abstract][Full Text] [Related]
12. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904 [TBL] [Abstract][Full Text] [Related]
13. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512 [TBL] [Abstract][Full Text] [Related]
14. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. Corpechot C; Chazouillères O; Poupon R J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194 [TBL] [Abstract][Full Text] [Related]
15. Natural history of pruritus in primary biliary cirrhosis. Talwalkar JA; Souto E; Jorgensen RA; Lindor KD Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671 [TBL] [Abstract][Full Text] [Related]
16. The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense. Van Den Bogaert E; Francque S; Pelckmans P; Michielsen P Acta Gastroenterol Belg; 2003; 66(4):283-7. PubMed ID: 14989050 [TBL] [Abstract][Full Text] [Related]
17. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577 [TBL] [Abstract][Full Text] [Related]
18. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724 [TBL] [Abstract][Full Text] [Related]
19. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate. Lee YM; Kaplan MM Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]